On the marketing and use of pharmacogenetic tests for psychiatric treatment

JAMA Psychiatry

Volumn 75, Issue 8, 2018, Pages 769-770

  Zubenko, George S ^a   Sommer, Barbara R ^b   Cohen, Bruce M ^c,d  

^a AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMNESIS; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CONFLICT OF INTEREST; CONSUMER; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; GENETIC VARIABILITY; HUMAN; MAJOR DEPRESSION; MARKETING; PHARMACOGENETIC TESTING; PRIVATE HEALTH INSURANCE; PSYCHIATRIC TREATMENT; PUBLIC HEALTH INSURANCE; REVIEW; TREATMENT RESPONSE; ADVERSE DRUG REACTION; COST; ECONOMICS; GENETIC SCREENING; GENETICS; PHARMACOGENETICS; PROCEDURES; REPRODUCIBILITY; TREATMENT OUTCOME;

PSYCHOTROPIC AGENT;

COSTS AND COST ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC TESTING; HUMANS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 85051003842     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2018.0834     Document Type: Review

References (8)

1. GeneSight.com. Replace Trial and Error With Triumph. https://genesight.com/. Accessed March 29, 2018.
2. Tansey KE, Guipponi M, Perroud N, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med. 2012;9(10): e1001326.
3. GENDEP Investigators; MARS Investigators; STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013; 170(2):207-217.
4. Demkow U, Wolańczyk T. Genetic tests in major psychiatric disorders-integrating molecular medicine with clinical psychiatry: why is it so difficult? Transl Psychiatry. 2017;7(6):e1151.
5. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141.
6. Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18(3):273-287.
7. Dubovsky SL. The limitations of genetic testing in psychiatry. Psychother Psychosom. 2016;85(3): 129-135.
8. Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? a systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017; 78(6):720-729.